Doorgaan naar hoofdnavigatie
Doorgaan naar zoeken
Ga verder naar hoofdinhoud
Sorteer per
Medicine and Dentistry
Neoplasm
100%
Wilms' Tumor
88%
Chemotherapy
73%
Breast Cancer
59%
Non Small Cell Lung Cancer
58%
Overall Survival
55%
Kidney Tumour
53%
Radiation Therapy
50%
Childhood Cancer
39%
Recurrent Disease
37%
Positron Emission Tomography
33%
Disease
31%
Malignant Neoplasm
29%
Fluorodeoxyglucose F 18
28%
Pediatrics
26%
Surgery
25%
Polyethylene Terephthalate
24%
Hazard Ratio
23%
Randomized Controlled Trial
21%
Lymph Node
21%
Obstructive Sleep Apnea
20%
Melanoma
20%
Colorectal Carcinoma
20%
Event Free Survival
20%
Squamous Cell Carcinoma
19%
Arm
19%
Metastatic Carcinoma
19%
Systemic Therapy
19%
Hyperthermic Intraperitoneal Chemotherapy
18%
Preoperative Chemotherapy
18%
Adverse Event
18%
Carboplatin
18%
Cisplatin
16%
Lung Cancer
16%
Prognostic Factor
15%
Drug Megadose
15%
Penis Carcinoma
14%
Cystectomy
14%
Carcinomatous Peritonitis
13%
Biopsy Technique
13%
Computer Assisted Tomography
13%
High Dose Chemotherapy
13%
Pediatrics Patient
13%
Doxorubicin
12%
Bevacizumab
12%
Progression Free Survival
12%
Chemoradiotherapy
12%
Scintigraphy
12%
Phallus
12%
Sentinel Node
11%
Keyphrases
Wilms Tumor
72%
Tumor
66%
Overall Survival
49%
Chemotherapy
49%
Radiotherapy
38%
Non-small Cell Lung Cancer (NSCLC)
36%
Confidence Interval
35%
Renal Tumor
35%
Tumor Research
33%
Dutch
31%
Carboplatin
26%
Pediatric Oncology
26%
Netherlands
25%
Breast Cancer
23%
Preoperative Chemotherapy
23%
Hazard Ratio
23%
Randomized Trial
23%
Breast Cancer Patients
23%
Positron Emission Tomography
23%
Phase II Study
23%
Bevacizumab
22%
Colorectal Cancer
21%
Capecitabine
21%
Event-free Survival
20%
Cisplatin
19%
5-year Survival
19%
High Risk
17%
18F-fluorodeoxyglucose Positron Emission Tomography (18F-FDG PET)
17%
Head-and-neck Cancer
17%
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
17%
Penile Carcinoma
16%
Obstructive Sleep Apnea-hypopnea Syndrome (OSAHS)
16%
Progression-free Survival
16%
Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
16%
70-gene Signature
16%
Primary Tumor
16%
Intermediate Risk
16%
Metastatic Breast Cancer
16%
Prophylactic Cranial Irradiation
15%
Neoadjuvant
15%
Computed Tomography
15%
Doxorubicin
15%
Erlotinib
15%
High-dose Chemotherapy
14%
Tumor Volume
14%
High Dose
14%
Randomized Phase III Trial
14%
Peritoneal Carcinomatosis
13%
International Society
13%
Breast Cancer Risk
13%
Pharmacology, Toxicology and Pharmaceutical Science
Chemotherapy
74%
Neoplasm
68%
Breast Cancer
52%
Overall Survival
38%
Non Small Cell Lung Cancer
36%
Carboplatin
26%
Disease
26%
Progression Free Survival
24%
Polyethylene Terephthalate
22%
Malignant Neoplasm
22%
Cisplatin
21%
Nephroblastoma
20%
Recurrent Disease
19%
Randomized Controlled Trial
18%
Capecitabine
18%
Paclitaxel
18%
Metastatic Breast Cancer
18%
Bevacizumab
17%
Cyclophosphamide
16%
Fluorodeoxyglucose F 18
16%
Doxorubicin
15%
Melanoma
14%
Kidney Tumour
14%
Sleep Disordered Breathing
13%
Chemoradiation Therapy
12%
Erlotinib
12%
Tamoxifen
12%
Recurrence Free Survival
11%
Ipilimumab
11%
High Dose Chemotherapy
11%
Adverse Event
10%
Immunotherapy
10%
Lung Cancer
10%
Bladder Cancer
10%
Etoposide
9%
Small Cell Lung Cancer
9%
Abdominal Cancer
9%
Colon Carcinoma
9%
Estrogen Receptor
8%
Base
8%
Solid Malignant Neoplasm
8%
Colorectal Carcinoma
8%
Brain Metastasis
7%
Esophagus Cancer
7%
Event Free Survival
7%
Docetaxel
7%
Epidermal Growth Factor Receptor
7%
Intraperitoneal Chemotherapy
6%
Randomized Clinical Trial
6%
Larynx Carcinoma
6%
